Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
Immunovant (Nasdaq: IMVT) announced on May 23, 2022, that CEO Pete Salzmann will participate in a fireside chat at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) announced on May 23, 2022, that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.
The chat is scheduled for May 25 at 12:30 pm ET and will be available via webcast on the company's Investor Relations page at www.immunovant.com.
Immunovant focuses on developing innovative therapies for autoimmune diseases, notably their investigational compound, batoclimab.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +0.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, taking place May 23rd-26th, 2022.
H.C. Wainwright Global Investment Conference fireside chat details:
| Date: | Wednesday, May 25th, 2022 |
| Time: | 12:30 pm Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com. |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.